2 high-quality ASX 200 blue chip shares to buy with $2,000 in February

These shares are highly rated by analysts at Bell Potter. But why?

| More on:
Excited couple celebrating success while looking at smartphone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new month is here, so what better time to make some new additions to your ASX investment portfolio.

If you are interested in ASX 200 blue chip shares and have $2,000 to invest, then it could pay to listen to what Bell Potter is saying about the two listed below.

Here's why they blue chips could be top buys in February:

Brickworks Ltd (ASX: BKW)

The first ASX 200 blue chip share that Bell Potter is positive on is Brickworks.

It specialises in property, investments, and the manufacture and distribution of building products for the residential and commercial markets.

Bell Potter is bullish and believes that it is positioned to benefit from interest rate cuts. The broker said:

We see BKW as a high delta exposure to interest rate cuts and by extension a stock to own as we edge closer to the cycle pivot point (Bell Potter's base case for our first cut is 1H CY25). Specifically, we see a scenario unfolding where BKW could realise double digit mark-to-market NTA growth p.a. quite comfortably in coming years through positive revals (i.e. cap rate reversal), ongoing property development and rent reversion (BKW remains ~28% underrented and 50% short-WALE), as well as continued SOL outperformance. This is a growth story we think few ASX-200 industrials can currently match.

Bell Potter has a buy rating and $32.00 price target on its shares.

CSL Ltd (ASX: CSL)

Another ASX 200 blue chip share for that $2,000 investment could be CSL. It is the biotechnology giant behind the CSL Behring, CSL Vifor, and CSL Seqirus businesses.

Bell Potter believes that the company is well-positioned to deliver on its medium term earnings growth guidance. This is expected to be driven by strong demand for immunoglobulins and margin expansion in the key CSL Behring business.

Commenting on the company, the broker said:

We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings.

CSL continues to be a high quality, global operator with a multi-year gross margin recovery well underway to drive earnings expansion. The stock is currently trading at a 12m forward PE 27% and 19% below 5- and 10-year averages, respectively.

Bell Potter has a buy rating and $345.00 price target CSL's shares.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Brickworks and CSL. The Motley Fool Australia has positions in and has recommended Brickworks. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Blue Chip Shares

2 of the best ASX 200 blue chip shares to buy with $2,000

One leading broker has very good things to say about these buy-rated shares.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Blue Chip Shares

Is it too late to buy this $33 billion ASX 200 stock?

Do analysts think this popular stock can deliver good returns for investors? Let's find out.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

The one Australian stock to buy and hold forever in an ASX share portfolio

Buy and hold investing could be your ticket to wealth. Let's see why.

Read more »

Six smiling health workers pose for a selfie.
Blue Chip Shares

Should you buy CSL and ResMed shares in January?

Let's see what one leading broker is saying about these blue chips.

Read more »

Two people tired and resting after sports race.
Blue Chip Shares

Value + yield: 2 battered blue-chip ASX dividend shares that demand attention

I think these stocks could be very compelling for income.

Read more »

Excited couple celebrating success while looking at smartphone.
Blue Chip Shares

3 of the best ASX 200 blue chip shares to buy in January

Let's see why brokers are tipping these blue chips as buys this month.

Read more »

A man is shocked about the explosion happening out of his brain.
Blue Chip Shares

3 no-brainer ASX 200 blue chip stocks to buy this month

Analysts think these stocks are high quality options for blue chip investors.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Blue Chip Shares

These ASX 200 blue chip shares could rise 30% in 2025

Brokers think these blue chips could be market-beaters in 2025. Let's find out why.

Read more »